MAPK7 and non-small cell lung carcinoma: As expected, our data suggested that ERK5 siRNA or the ERK5 inhibitor XMD8-92 preferentially increased NSCLC cell sensitivity to IR treatment and enhanced the radiotherapeutic index of lung cancer.